Friday, July 17, 2026
🇺🇸 FDA

QA/QC Tools · Deviation · GMP · ICH Q10

Pharmaceutical Deviation Report Template

Interactive GMP deviation report covering planned and unplanned deviations, risk classification, root cause investigation, and CAPA linkage. Qualio and Docsie offer eQMS or static templates; this tool adds auto-save, 6M RCA, and dynamic CAPA action rows.

Quick Answer

A pharmaceutical deviation is any departure from an approved instruction, procedure, specification, or established standard during manufacturing, testing, or storage. This interactive GMP deviation report covers planned and unplanned events with risk classification (Critical/Major/Minor), root cause investigation using the 6M framework, impact assessment, CAPA linkage, and QA closure. Document within 24 hours of discovery per typical SOPs; Critical deviations target 30-day closure. Auto-saves locally in your browser.

Section 1 — Deviation Header
Section 2 — Deviation Classification
Section 3 — Deviation Description
Section 4 — Immediate Actions Taken
Section 5 — Impact Assessment
Section 6 — Root Cause Investigation
Section 7 — CAPA Actions

Link to your CAPA system and list corrective/preventive actions resulting from this deviation.

Section 8 — Closure

How to Use This Template

1
Generate a deviation number and complete header fields—date detected, department, reporter.
2
Classify as planned or unplanned; assign category, risk level, and GMP impact.
3
Document the event, containment actions, quarantine status, and affected batches.
4
Complete impact assessment and root cause investigation using 6M categories.
5
Link CAPA actions, obtain QA approval, and print/save PDF. Form auto-saves every 5 seconds.

Pharma / GMP Context for QA Professionals

Deviation management is the front line of pharmaceutical quality event detection. Every batch record review under 21 CFR 211.192 must investigate unexplained discrepancies—failure to connect shop-floor events to formal deviation records is a recurring FDA observation theme. Trend analysis of deviation categories feeds management review and proactive CAPA under ICH Q10.

Planned deviations require pre-approval with defined scope and duration; unplanned deviations demand immediate containment and retrospective investigation. Risk classification drives closure timelines and regulatory reporting obligations. Critical deviations affecting distributed product may trigger field alert or recall assessment.

Escalate systemic root causes to the CAPA Template. Laboratory test failures linked to deviations use the OOS Investigation Template. Pre-audit gap identification uses the GMP Checklist Generator.

Evidence and Sources

Frequently Asked Questions

A pharmaceutical deviation is any departure from an approved instruction, procedure, specification, or established standard during manufacturing, testing, or storage. Deviations can be planned (anticipated and pre-approved) or unplanned (unexpected, discovered during or after an operation). All deviations must be documented, investigated, and formally closed per GMP requirements including EU GMP Chapter 5, FDA 21 CFR 211, and ICH Q10.
A planned deviation is a pre-approved, temporary departure from a standard operating procedure or specification—the deviation is known and assessed before it occurs (e.g., using backup equipment during maintenance). An unplanned deviation is unexpected and discovered during or after the operation, requiring retrospective investigation and root cause analysis. Both require documentation and QA approval.
Critical deviations always require CAPA. Major deviations typically require CAPA unless the investigation clearly shows a one-time, non-systemic event. Minor deviations may require CAPA if they are recurring. CAPA is triggered when the root cause is systemic, when recurrence prevention requires process/SOP changes, or when regulatory compliance is impacted.
Industry standard: Critical deviations within 30 days; Major within 60 days; Minor within 90 days. Closure requires completed root cause investigation, implemented corrective actions, and QA approval. Extensions require documented justification and management approval. Overdue deviations are among the most common FDA 483 observations.
Critical deviation: direct or potential impact on patient safety or product quality that could result in recall or regulatory action. Major deviation: significant but not immediately life-threatening—potential impact on product quality or compliance. Minor deviation: unlikely to affect product quality or patient safety—primarily documentation or procedural non-conformance.
Contain the affected material (quarantine/hold), halt production if necessary, notify QA within the timeframe defined in site SOP (often 24 hours), preserve evidence (batch records, logs, samples), and document containment actions in Section 4 of this template before beginning root cause investigation.
The 6M categories are Man (personnel), Machine (equipment), Material, Method (procedure), Environment, and Measurement. Select all applicable categories during investigation to ensure multidimensional analysis. A verified root cause must be specific, actionable, and supported by evidence—not generic labels like "human error" without systemic context.
Batch release after a deviation requires completed impact assessment confirming no adverse effect on product quality, QA review, and documented justification in the deviation closure record. Critical deviations affecting product attributes typically require batch rejection, rework, or additional testing per approved procedures—not automatic release.
A deviation is a process or procedural departure (e.g., temperature excursion, missed line clearance). An OOS (Out-of-Specification) result is a laboratory test result outside acceptance criteria. An OOS may trigger a deviation record; conversely, some deviations (documentation errors with no testing impact) do not involve OOS. Use the OOS Investigation Template for analytical failures.
FDA 21 CFR 211.100 requires written procedures and deviations documented with justification. 21 CFR 211.192 requires production record review and investigation of any unexplained discrepancy. EU GMP Chapter 1 and Chapter 5 require deviation recording and investigation. ICH Q10 integrates deviation management into the pharmaceutical quality system.
No. Commercial manufacturers typically use validated eQMS platforms (Qualio, Veeva, MasterControl) with audit trails and electronic signatures under 21 CFR Part 11. This template supports drafting, training, and sites without eQMS—auto-saves to browser localStorage. Export via print/PDF for manual quality systems.
Link deviations to the CAPA Template for systemic corrections, OOS Investigation for laboratory failures, GMP Checklist Generator for audit-prevention, Stability Schedule Generator for missed stability pulls, and RPN Calculator for proactive risk assessment under ICH Q9.

Related Tools

📋CAPA Template 🔬OOS Investigation ☰RPN Calculator ✅GMP Checklist

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.